1. For the pharmacological treatment of patients with gastroesophageal reflux disease (GERD), long-term acid suppressive therapy (proton pump inhibitors or H2 receptor antagonists) should be reduced to the lowest effective dose required to achieve the therapeutic goal. The main identifiable risk associated with the reduction or discontinuation of acid suppression therapy is an increased symptom burden. It can be concluded that decisions regarding the need for maintenance therapy (versus dose) are driven by the impact of residual symptoms on the patient’s quality of life and cannot be used as an indicator of disease control. 2. Individuals at average risk do not require repeat colorectal cancer screening by any method for 10 years after a single high-quality colonoscopy is negative. For adults with no increased risk of colorectal cancer, every 10 years is recommended as an interval for colonoscopy screening. Published studies have shown that this population has a lower risk of cancer 10 years after a single high-quality colonoscopy that did not detect a tumor. Therefore, after one high-quality colonoscopy with normal results, the next time for any colorectal cancer screening is 10 years thereafter. 3. Patients with 1 or 2 small adenomatous polyps (< 1 cm) but no high-grade heterogeneous hyperplasia do not require repeat colonoscopy for at least 5 years after complete removal of the polyps by high-quality colonoscopy. The timing of follow-up surveillance colonoscopy should be determined based on the results of a previous high-quality colonoscopy. Evidence-based guidelines recommend that patients with 1 or 2 small tubular adenomas with low-grade heterogeneous hyperplasia undergo surveillance colonoscopy 5 to 10 years after the initial polypectomy. The exact timing within this interval should be based on other clinical factors (e.g., results of the previous colonoscopy, family history, and patient selection and physician judgment). 4. In patients with a diagnosis of Barrett's esophagus, if a second endoscopy is performed to confirm the absence of heterogeneous hyperplasia on biopsy, follow-up surveillance examinations should not be performed for up to 3 years according to published guidelines. In patients with Barrett's esophagus without heterogeneous hyperplasia (cellular changes), the risk of cancer is extremely low. In these patients, it is appropriate and safe to examine the esophagus and the presence or absence of heterogeneous hyperplasia once every 3 years and beyond, due to the fact that even if these cellular changes occur, they progress very slowly. 5. In patients with functional abdominal pain syndrome (diagnosed according to Rome III criteria), computed tomography (CT) scans should not be repeated unless there is a major change in clinical presentation or symptoms. Increased cancer risk with x-ray exposure. A CT scan of the abdomen is one of the X-rays with a high radiation exposure, equivalent to 3 years of natural background radiation. Because of the risks involved and the high cost of this operation, CT scans should only be performed when they may provide useful information that may alter the patient's treatment. This information is for informational purposes only and is not a substitute for professional medical consultation. Patients who have questions about this list or their own situation should consult with a medical professional.